Table 1.

Summary of available clinical trial data

Trial Name/NCT No.Study DesignN, PopulationeGFR CutoffRemdesivir Duration, dOutcomes
NIAID ACTT-1 studyDouble-blind, placebo-controlled RCT1063 hospitalized adult patients, international3010Interim analysis: median time to recovery 11 versus 15 d; P<0.001; mortality 8% versus 11.6%; P=0.06
NCT04292899Randomized, open-label trial197 adults with severe COVID-19, international505 versus 1070% clinical recovery and 59% clinical recovery by 14 d in 5- and 10-d groups
Compassionate use programOpen label, multicenter, nonrandomized>1200 adults, 76 children with COVID-19, international3010Report of 61 treated patients, 8 lost to follow-up; 36 of 53 improved at a median follow-up of 18 d2
NCT04257656Double-blind, placebo-controlled RCT237 adults with severe COVID-19, China3010No difference in time to clinical improvement; equivalent number of renal AEs in placebo and remdesivir arms3
  • In all cases, remdesivir dosing begins with a 200-mg intravenous loading dose followed by 100 mg intravenously daily. Currently available clinical trial data supporting remdesivir use are shown. NCT, national clinical trial; NIAID ACTT-1, National Institute of Allergy and Infectious Diseases Adaptive Covid-19 Treatment Trial; RCT, randomized, controlled trial; AE, adverse event.